Pseudomonas aeruginosa

Pseudomonas aeruginosa is a rod-shaped, motile (single polar flagellum and Type IV pili), non-spore-forming Gram-negative bacterium in the class Gammaproteobacteria (Pseudomonadaceae). Capable of aerobic respiration using O₂ as the terminal electron acceptor as well as anaerobic denitrification on nitrate (NO₃⁻) and nitrite (NO₂⁻) or arginine substrate-level phosphorylation, P. aeruginosa inhabits soil, freshwater, coastal marine environments, and hospital plumbing systems. In clinical medicine, it is a premier member of the ESKAPE pathogens and the primary cause of chronic pulmonary decline in patients with cystic fibrosis (CF), as well as a leading etiological agent of ventilator-associated pneumonia, burn-wound sepsis, and contact-lens-associated keratitis.

The versatility and intrinsic antimicrobial resistance of P. aeruginosa are encoded by a large, GC-rich genome (6.2 to 7.1 Mb, with ~66.6% G+C content and ~5,570–6,500 open reading frames in reference strains PAO1 and PA14). Over 8% of its coding capacity is dedicated to two-component signal transduction systems, transcriptional regulators, and metabolic transporters. In addition to a conserved core genome (~4,500 genes), clinical P. aeruginosa clones maintain an expansive accessory pangenome assembled within chromosomal regions of genomic plasticity (RGPs), where integrative and conjugative elements (ICEs), prophages, and Class 1 integrons insert into tRNA genes (tRNA-Gly, tRNA-Ser, tRNA-Phe).

Low Outer-Membrane Permeability, OprD Porin Loss, and Chromosomal AmpC

The baseline intrinsic resistance of P. aeruginosa to aminopenicillins, first- and second-generation cephalosporins, macrolides, tetracyclines, and trimethoprim stems from the synergy between an unusually impermeable outer membrane and an inducible chromosomal cephalosporinase. Unlike Escherichia coli, which expresses abundant non-specific trimeric general diffusion porins (OmpF and OmpC) that allow rapid passive diffusion of hydrophilic molecules up to ~600 Da, P. aeruginosa lacks general diffusion porins. Its major outer-membrane structural protein, OprF, folds predominantly (~95%) as a closed two-domain conformer (an N-terminal 8-stranded β-barrel plugged by a C-terminal periplasmic peptidoglycan-binding domain), leaving only ~5% of OprF molecules in an open 16-stranded channel conformation. Consequently, the outer-membrane permeability coefficient of P. aeruginosa to β-lactams is only ~1% to 8% that of E. coli.

Instead of general porins, P. aeruginosa relies on ~26 substrate-specific channels, chief among which is OprD (OccD1), a 443-residue monomeric 18-stranded β-barrel porin that facilitates the uptake of basic amino acids (arginine, lysine, histidine, ornithine) and short basic peptides. Zwitterionic carbapenems—particularly imipenem and meropenem—exploit OprD as their primary portal of entry into the periplasm. Under carbapenem selection in the clinic, P. aeruginosa rapidly acquires frameshift insertions, premature stop codons, IS element disruptions, or transcriptional down-regulation (MexT-mediated) of oprD. When OprD loss is combined with derepression of the chromosomal Ambler Class C cephalosporinase AmpC (Pseudomonas-derived cephalosporinase, PDC)—triggered by inactivating mutations in the peptidoglycan-recycling amidase AmpD or the penicillin-binding protein PBP4 (dacB)—imipenem and meropenem MICs rise from ≤1 μg/mL to 16–32 μg/mL even without an acquired carbapenemase.

The Four RND Tripartite Efflux Systems and Acquired Metallo-β-Lactamases

To reinforce outer-membrane exclusion, P. aeruginosa encodes 12 Resistance-Nodulation-Division (RND) efflux pumps, four of which dominate clinical multidrug resistance by harnessing the inner-membrane proton-motive force (PMF, H⁺ antiport) to extrude substrates across both membranes:

1. MexAB-OprM: Constitutively expressed in wild-type strains (PAO1) and hyper-expressed upon inactivation of its local repressors (mexR, nalC, or nalD). It exports meropenem (specifically recognizing its C2 side chain, whereas imipenem lacks this side chain and is not a MexAB-OprM substrate), antipseudomonal penicillins (piperacillin, ticarcillin), cephalosporins (ceftazidime, cefepime), aztreonam, fluoroquinolones, tetracyclines, and chloramphenicol.
2. MexXY (paired with OprM or OprA): Inducible by ribosome-targeting antibiotics via the MexZ repressor and ArmZ anti-repressor; serves as the primary mechanism of intrinsic and adaptive resistance to aminoglycosides (tobramycin, amikacin, gentamicin) as well as cefepime and fluoroquinolones.
3. MexCD-OprJ: Normally silent, but derepressed by loss-of-function mutations in nfxB, conferring resistance to fluoroquinolones, fourth-generation cephalosporins (cefepime, cefpirome), and macrolides while often inducing collateral hypersensitivity to imipenem and aminoglycosides.
4. MexEF-OprN: Activated by the LysR-type regulator MexT (which simultaneously represses oprD transcription), driving co-resistance to fluoroquinolones, chloramphenicol, trimethoprim, and imipenem.

In global high-risk clones (ST235, ST111, and ST175), chromosomal OprD and AmpC mutations are compounded by the horizontal acquisition of Class B1 metallo-β-lactamases (blaVIM-2, blaNDM-1, blaIMP-1) or Class A carbapenemases (blaGES-5, blaKPC-2). These cassettes are carried inside Class 1 integrons embedded within 70–120 kb chromosomal genomic islands (PAPI-1-like integrative and conjugative elements) integrated at tRNA-Gly or tRNA-Ser attB sites, where sliding-window tetranucleotide Kullback–Leibler divergence clearly demarcates the exogenous foreign island (GC ~52–58%) against the 66.6% GC host chromosome.

Hierarchical Las, Rhl, and PQS Quorum Sensing and Cystic Fibrosis Mucoidy

To coordinate population-density-dependent transitions between acute planktonic virulence and chronic biofilm persistence, P. aeruginosa employs an interconnected three-tier quorum sensing (QS) network:

• The LasI/LasR System: Synthesizes and senses N-(3-oxododecanoyl)-L-homoserine lactone (3-oxo-C12-HSL), activating transcription of elastase (lasB, lasA), alkaline protease (aprA), exotoxin A (toxA, which ADP-ribosylates eukaryotic elongation factor 2 eEF-2), and the downstream rhl and pqs systems.
• The RhlI/RhlR System: Synthesizes N-butyryl-L-homoserine lactone (C4-HSL), controlling production of rhamnolipid biosurfactants (rhlAB), hydrogen cyanide (hcnABC), and the redox-active phenazine pigment pyocyanin (which generates superoxide O₂^•− and H₂O₂ in host airway epithelium).
• The PQS (Pseudomonas Quinolone Signal) System: Synthesizes 2-heptyl-3-hydroxy-4-quinolone (PQS via pqsABCD and pqsH), which binds the LysR-type regulator PqsR (MvfR), chelates ferric iron (Fe³⁺), and induces outer-membrane vesicle (OMV) biogenesis and autolytic release of structural extracellular DNA (eDNA).

During chronic colonization of the dehydrated, mucus-plugged airways of patients with cystic fibrosis (caused by CFTR chloride-channel deficiency), P. aeruginosa undergoes predictable within-host evolutionary adaptation. Isolates frequently acquire loss-of-function mutations in mucA (encoding an inner-membrane anti-sigma factor that sequesters the extracytoplasmic sigma factor AlgU, also termed σ22). Liberated AlgU activates the algD operon, driving high-level overproduction of alginate, an O-acetylated linear copolymer of β-1,4-linked D-mannuronic acid and α-L-guluronic acid. Combined with the neutral/cationic exopolysaccharides Psl (pslA–O, mannose/glucose/rhamnose pentasaccharide repeat) and Pel (pelA–G, partially de-N-acetylated α-1,4-N-acetylgalactosamine that ionically cross-links anionic eDNA), the mucoid alginate matrix shields microcolonies from neutrophil phagocytosis, complement opsonization, and inhaled tobramycin.

Type III Secretion System (T3SS) Injectisome: ExoU vs. ExoS Clonal Dichotomy

In acute invasive infections (such as ventilator-associated pneumonia and bacteremic shock), P. aeruginosa deploys a needle-like Type III Secretion System (T3SS) injectisome to translocate four effector toxins (ExoS, ExoT, ExoU, and ExoY) directly across the eukaryotic host plasma membrane. Across the species pangenome, clinical isolates exhibit a striking mutual exclusion between exoS (present in ~70–80% of isolates, such as PAO1 and ST111) and exoU (carried on genomic island PAPI-2 in ~20–28% of isolates, notably PA14 and the pandemic clone ST235):

• ExoS is a bifunctional toxin possessing an N-terminal Rho GTPase-activating protein (GAP) domain that disrupts the host actin cytoskeleton and a C-terminal ADP-ribosyltransferase (ADPRT) domain activated by host 14-3-3 proteins (FAS) that promotes intracellular invasion and apoptosis.
• ExoU (74 kDa, chaperoned by SpcU) is a patatin-like phospholipase A₂ (PLA2) activated upon binding host intracellular ubiquitin or polyubiquitinated proteins and phosphatidylinositol 4,5-bisphosphate (PIP2) at the inner leaflet of the host plasma membrane. Once activated, ExoU cleaves membrane phospholipids into lysophospholipids and arachidonic acid, causing rapid necrotic lysis of alveolar macrophages and pneumocytes, barrier breakdown, and septic shock associated with high 30-day patient mortality.

Why is imipenem affected by OprD porin loss while meropenem is also affected by MexAB-OprM efflux?

Both imipenem and meropenem rely on the basic-amino-acid porin OprD to cross the low-permeability outer membrane of Pseudomonas aeruginosa, so loss of OprD raises the MIC of both carbapenems. However, once inside the periplasm, meropenem possesses a bulky heterocyclic C2 side chain with a weakly hydrophobic character that makes it a substrate for capture and extrusion by the MexAB-OprM RND efflux pump. Imipenem has a smaller, more hydrophilic formimidoyl C2 substituent that avoids recognition by MexB, meaning MexAB-OprM overexpression selectively elevates meropenem MICs without altering imipenem susceptibility.

How does ceftolozane–tazobactam overcome classical Pseudomonas resistance, and how does resistance to it emerge?

Ceftolozane is an oxyimino-aminothiazolyl cephalosporin engineered with a bulky pyrazole ring at the 3-position side chain that sterically hinders binding and hydrolysis by wild-type chromosomal AmpC (PDC), while remaining unaffected by OprD porin loss and MexAB-OprM or MexXY efflux. However, under prolonged clinical exposure (or in metallo-β-lactamase producers like blaVIM-2 and blaNDM-1), P. aeruginosa can evolve resistance to ceftolozane–tazobactam via structural point mutations or deletions within the Ω-loop of chromosomal AmpC (such as E247K, G183D, or T96I, designated PDC extended-spectrum variants), which widen the active-site binding pocket to hydrolyze ceftolozane while simultaneously reducing PBP3 acylation by tazobactam.

Why does Pseudomonas aeruginosa turn blue-green on agar plates and emit a grape-like odor?

Pseudomonas aeruginosa synthesizes two water-soluble secondary pigments that diffuse into the growth medium: pyocyanin (a blue redox-active phenazine pigment synthesized via the phzA1–G1 and phzM/phzS pathways) and pyoverdine (a yellow-green fluorescent peptidic siderophore that chelates Fe³⁺ with a binding constant of ~10³² M⁻¹), whose combined optical absorption produces the classic blue-green appearance in culture and infected wound dressings. The characteristic sweet, grape-like or corn-tortilla aroma is produced by 2-aminoacetophenone (2-AA), a volatile intermediate spun off from the anthranilate/quinolone (PQS) biosynthetic pathway.

1. Stover, C. K., Pham, X. Q., Erwin, A. L., Mizoguchi, S. D., Warrener, P., Hickey, M. J., Brinkman, F. S. L., Hufnagle, W. O., Kowalik, D. J., Lagrou, M., Garber, R. L., Goltry, L., Tolentino, E., Westbrock-Wadman, S., Yuan, Y., Brody, L. L., Coulter, S. N., Folger, K. R., Kas, A., Larbig, K., Lim, R., Smith, K., Spencer, D., Wong, G. K.-S., Wu, Z., Paulsen, I. T., Reizer, J., Saier, M. H., Hancock, R. E. W., Lory, S., & Olson, M. V. (2000). "Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen." Nature, 406(6799), 959–964. https://doi.org/10.1038/35023079
2. Lister, P. D., Wolter, D. J., & Hanson, N. D. (2009). "Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms." Clinical Microbiology Reviews, 22(4), 582–610. https://doi.org/10.1128/CMR.00040-09
3. Oliver, A., Mulet, X., López-Causapé, C., & Juan, C. (2015). "The increasing threat of Pseudomonas aeruginosa high-risk clones." Drug Resistance Updates, 21–22, 41–59. https://doi.org/10.1016/j.drup.2015.08.002
4. Hauser, A. R. (2009). "The type III secretion system of Pseudomonas aeruginosa: infection by injection." Nature Reviews Microbiology, 7(9), 654–665. https://doi.org/10.1038/nrmicro2199